Multiple sclerosis (MS) is a chronic disease of the central nervous system, specifically classified as an autoimmune condition. In MS, the body’s immune system mistakenly attacks the protective coating around nerve fibers in the brain and spinal cord, disrupting the electrical signals that travel between the brain and the rest of the body. Roughly 2.9 million people worldwide are living with MS, a number that has climbed from 2.3 million in 2013.
What Happens Inside the Body
The protective coating around your nerve fibers is called myelin. Think of it like the insulation on an electrical wire. In MS, immune cells that normally defend against infections become misdirected and begin attacking this insulation instead. Specifically, certain white blood cells become activated and cross from the bloodstream into the brain and spinal cord, where they trigger inflammation and damage.
Two types of immune cells play central roles. T-cells act as the primary attackers, releasing inflammatory chemicals that damage tissue. B-cells amplify the problem by presenting fragments of myelin to T-cells, essentially flagging normal tissue as a threat. In people with MS, B-cells show an abnormally high capacity to activate these inflammatory T-cells and secrete elevated levels of inflammatory signaling molecules while producing fewer of the anti-inflammatory ones that would normally keep the immune response in check.
When myelin is destroyed, the nerve fiber underneath can also be damaged. The location of each damaged spot, called a lesion, determines what symptom appears. A lesion in the part of the brain that controls vision causes visual problems. One in the spinal cord might cause leg weakness or numbness. This is why MS symptoms vary so widely from person to person.
Common Symptoms
MS can affect nearly any function controlled by the brain or spinal cord. During a flare-up (called a relapse), common symptoms include loss of vision in one eye, weakness in an arm or leg, and a rising sense of numbness in the legs. Beyond relapses, many people experience ongoing issues like muscle spasms, profound fatigue, depression, bladder control problems, sexual dysfunction, and difficulty walking. Cognitive changes, such as trouble with memory or concentration, also affect a significant portion of people with the condition.
No two people experience MS identically. Some have mild symptoms for years, while others develop significant disability more quickly. The unpredictability is one of the most challenging aspects of living with the disease.
Types and How MS Progresses
MS is broadly divided into phases based on how it behaves over time. The most common pattern is the relapsing-remitting phase, where symptoms flare up for days or weeks and then partially or fully resolve. About 85% of people with MS start with an initial episode called a clinically isolated syndrome, a single neurological event lasting at least 24 hours that may or may not progress. Studies show that roughly 70% of people who experience this first episode go on to meet the full criteria for MS within two years, though reported conversion rates range from 30% to 82% depending on the study.
Over time, some people transition from the relapsing-remitting phase into a progressive phase, where neurological function gradually and irreversibly worsens regardless of relapses. This is called secondary progressive MS. A smaller group, diagnosed with primary progressive MS, experiences this steady decline from the very beginning without distinct relapses. The progressive phase tends to become noticeable around the mid-40s on average, and this timing appears to be driven more by age than by how long someone has had the disease.
As MS progresses further into later decades of life, the chance of experiencing acute relapses drops significantly, falling below 5% after the late 50s and below 1% after the 60s. However, the underlying progression can still continue.
How MS Is Diagnosed
There is no single test that confirms MS. Diagnosis relies on a combination of medical history, neurological examination, and several key tests, all while ruling out other conditions that can mimic MS.
- MRI scans are the most important tool. They reveal lesions (areas of damage) in the brain and spinal cord. A contrast dye injected during the scan can highlight active lesions, indicating ongoing inflammation.
- Lumbar puncture (spinal tap) collects cerebrospinal fluid to look for specific antibodies. The presence of certain markers, such as oligoclonal bands or kappa free light chains, supports the diagnosis.
- Evoked potential tests measure how quickly electrical signals travel through your nervous system in response to visual or other stimuli, which can reveal nerve damage not yet causing obvious symptoms.
- Eye imaging (optical coherence tomography) measures the thickness of the retina, since optic nerve inflammation is a common early feature of MS.
- Blood tests help exclude conditions that look similar, such as neuromyelitis optica spectrum disorder and MOG-associated disorder.
The diagnostic framework, known as the McDonald criteria, requires evidence that damage has occurred in at least two different areas of the central nervous system at two different points in time. This principle of “dissemination in space and time” helps distinguish MS from a single inflammatory event that might never recur.
Treatment Options
While there is no cure for MS, disease-modifying therapies (DMTs) can reduce the frequency of relapses, slow disability progression, and limit new inflammation in the brain and spinal cord. Starting treatment early makes a meaningful difference in long-term outcomes.
DMTs come in three main forms. Injectable therapies are typically self-administered at home on a schedule ranging from daily to weekly. Oral medications offer convenience but require consistent daily adherence. Infusion therapies are given at a medical facility, often on a less frequent schedule, sometimes only a few times per year. The choice depends on disease severity, personal preferences, and how the body responds.
Life Expectancy and Long-Term Outlook
MS is a lifelong condition, but it is not typically considered a fatal one in the short term. People diagnosed with MS who have not yet developed severe disability can expect a median survival of roughly 30 to 35 years after diagnosis. For someone diagnosed around age 33, that translates to a life expectancy of about 64 years. This represents a reduction of approximately one-third compared to the general population.
Disability level significantly influences the outlook. People who lose the ability to walk independently (typically in their early 50s on average) have about 13 additional years of life expectancy. Those who become wheelchair-dependent (around age 58 on average) have roughly 7 to 8 additional years. These numbers reflect historical data, and modern treatments are expected to improve outcomes for people diagnosed today, since more effective therapies have become available in recent years.
The wide range of possible outcomes is worth emphasizing. Some people live with mild MS for decades and maintain full independence, while others face more rapid progression. Early treatment, consistent monitoring, and a proactive approach to managing symptoms all contribute to better long-term results.